Amrubicin — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	4	3	8	22	—	—	2004-05
Malignant Lung Neoplasm	Phase3	Phase 3	4	3	8	15	—	—	2004-05
Malignant Bladder Neoplasm	Phase2	Phase 2	0	0	0	1	—	—	2011-02
Malignant Breast Neoplasm	Phase2	Phase 2	0	0	0	2	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NQO1 EXPRESSION1
Amrubicin	Malignant Lung Neoplasm

Clinical trials

Trials with this intervention (22)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–22 of 22 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07365241	A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer	recruiting	Phase 3	531	AbbVieINDUSTRY	10	Sep 23, 2026	clinicaltrials
NCT06801834	Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04)